DHR vs. RDY: Danaher vs. Dr. Reddy's Laboratories Stock Comparison

Company Profile

Danaher (DHR) and Dr. Reddy's Laboratories (RDY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but DHR is classified in Life Sciences Tools & Services while RDY is classified in Pharmaceuticals.

Danaher (DHR) trades as ordinary local shares, while Dr. Reddy's Laboratories (RDY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Danaher (DHR) at 8.19% and Dr. Reddy's Laboratories (RDY) at 7.34% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both Danaher (DHR) at 16.91% and Dr. Reddy's Laboratories (RDY) at 8.49% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Danaher (DHR) at 21.13% operates in the top operating margin quartile, ahead of Dr. Reddy's Laboratories (RDY) at 14.73%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Danaher (DHR) at 2.90% and Dr. Reddy's Laboratories (RDY) at 3.19% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Danaher (DHR) at -4.54% and Dr. Reddy's Laboratories (RDY) at -24.14% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Both Danaher (DHR) at 1.63 and Dr. Reddy's Laboratories (RDY) at 1.93 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Danaher (DHR) at 0.52 and Dr. Reddy's Laboratories (RDY) at 0.19 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Both Danaher (DHR) at 0.67% and Dr. Reddy's Laboratories (RDY) at 55.06% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Danaher (DHR) at 25.17% and Dr. Reddy's Laboratories (RDY) at 22.72% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Both Danaher (DHR) at 38.12 and Dr. Reddy's Laboratories (RDY) at 41.42 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Dr. Reddy's Laboratories (RDY) at 0.04 sits in the cheaper P/S ratio quartile while Danaher (DHR) at 6.32 prices around its industry’s middle — RDY costs less per dollar of sales, though read it alongside growth and margins.

Danaher (DHR) at 3.02 sits near its industry’s typical P/B ratio, while Dr. Reddy's Laboratories (RDY) at 18.16 prices above its benchmark range — RDY looks rich relative to book.

Valuation Metrics